Skip to main content
. 2020 May 3;75(8):2240–2248. doi: 10.1093/jac/dkaa147

Table 5.

Effect of predicted UGT1A1 activity on exposure to parenteral cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks) at Week 48 of the cabotegravir LA + rilpivirine LA maintenance phase of LATTE-2 (NCT02120352)

Endpoint Total n Association of genetically predicted UGT1A1 activity with endpoint
 Mean [n] (range) by predicted UGT1A1 activity stratum
 Fold-change in exposure (low vs normal)
P value parameter estimate (SE) normal reduced low
C tau (μg/mL) 159 0.0037 0.26 (0.10)

  • 1.88 [61]

  • (0–5.13)

  • 2.19 [75]

  • (0.19–5.49)

  • 2.32 [23]

  • (0–6.11)

 1.24
AUCtau (h·μg/mL) 212 0.0162 250.10 (116.08)

  • 2696 [81]

  • (323–9755)

  • 2762 [99]

  • (277–9288)

  • 3133 [32]

  • (1230–6256)

 1.16
C max (μg/mL) 212 0.0047 0.41 (0.16)

  • 3.53 [81]

  • (1.56–8.08)

  • 3.78 [99]

  • (1.03–10.5)

  • 4.16 [32]

  • (1.66–11.5)

 1.18
C avgi (μg/mL) 204 0.0094 0.19 (0.08)

  • 2.01 [78]

  • (0.46–4.51)

  • 2.12 [95]

  • (0.41–4.27)

  • 2.33 [31]

  • (0–6.73)

 1.16

SE, standard error.